Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Oculis has significant longer-term potential. However, it remains a high-risk investment given its clinical stage status, and ...

Lifecore Biomedical Inc (LFCR) is expected to report $-0.15 for 3Q. Lindsay Corp (LNN) is expected to report $1.89 for 2Q. MSC Industrial Direct Co - A Share (MSM) is expected to report $0.68 for 2Q.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold ...